Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Jul;26(1):31–34. doi: 10.1128/aac.26.1.31

Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

B M Farr, J M Gwaltney Jr, K F Adams, F G Hayden
PMCID: PMC179911  PMID: 6089652

Abstract

The prophylactic activity of intranasal human interferon-alpha 2 (HuIFN-alpha 2) against natural rhinovirus colds was determined in a randomized, double-blind, placebo-controlled trial. A total of 304 working adults self-administered sprays of HuIFN-alpha 2 (10(7) IU/day) or a placebo once daily. During 22 days of treatment, 13 (8.5%) placebo recipients but no HuIFN-alpha 2 recipients had respiratory illnesses documented secondary to rhinovirus infection (P = 0.0002). The occurrence of illness with symptoms of tracheobronchitis was lower in HuIFN-alpha 2 recipients (one eposide) than in placebo recipients (eight episodes, P = 0.04). In contrast, the frequency of nasal symptoms and the overall rate of respiratory illness were significantly higher in HuIFN-alpha 2 recipients during weeks 2 and 3 of treatment. Symptoms (obstruction, discomfort, blood-tinged nasal mucus) or signs (punctate bleeding sites, erosions, superficial ulcerations) of nasal irritation occurred in 40 HuIFN-alpha 2 recipients during week 3 (P less than 0.0001 versus placebo recipients). Although the results of the current study were partially confounded by the nasal side effects of prolonged administration, they showed that intranasal HuIFN-alpha 2 was efficacious in preventing rhinovirus colds under natural conditions.

Full text

PDF
31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dianzani F., Baron S. Unexpectedly rapid action of human interferon in physiological conditions. Nature. 1975 Oct 23;257(5528):682–684. doi: 10.1038/257682a0. [DOI] [PubMed] [Google Scholar]
  2. Greenberg S. B., Harmon M. W., Couch R. B., Johnson P. E., Wilson S. Z., Dacso C. C., Bloom K., Quarles J. Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. J Infect Dis. 1982 Apr;145(4):542–546. doi: 10.1093/infdis/145.4.542. [DOI] [PubMed] [Google Scholar]
  3. Greenberg S. B., Harmon M. W., Johnson P. E., Couch R. B. Antiviral activity of intranasally applied human leukocyte interferon. Antimicrob Agents Chemother. 1978 Oct;14(4):596–600. doi: 10.1128/aac.14.4.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gutterman J. U., Fine S., Quesada J., Horning S. J., Levine J. F., Alexanian R., Bernhardt L., Kramer M., Spiegel H., Colburn W. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982 May;96(5):549–556. doi: 10.7326/0003-4819-96-5-549. [DOI] [PubMed] [Google Scholar]
  5. Gwaltney J. M., Jr, Hendley J. O., Simon G., Jordan W. S., Jr Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966 Dec 8;275(23):1261–1268. doi: 10.1056/NEJM196612082752301. [DOI] [PubMed] [Google Scholar]
  6. Harmon M. W., Greenberg S. B., Johnson P. E. Rapid onset of the interferon-induced antiviral state in human nasal epithelial and foreskin fibroblast cells. Proc Soc Exp Biol Med. 1980 Jun;164(2):146–152. doi: 10.3181/00379727-164-40838. [DOI] [PubMed] [Google Scholar]
  7. Hayden F. G., Gwaltney J. M., Jr Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2. Antiviral Res. 1983 Mar;3(1):67–71. doi: 10.1016/0166-3542(83)90016-5. [DOI] [PubMed] [Google Scholar]
  8. Hayden F. G., Gwaltney J. M., Jr Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983 Sep;148(3):543–550. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  9. Hayden F. G., Mills S. E., Johns M. E. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis. 1983 Nov;148(5):914–921. doi: 10.1093/infdis/148.5.914. [DOI] [PubMed] [Google Scholar]
  10. Imanishi J., Karaki T., Sasaki O., Matsuo A., Oishi K., Pak C. B., Kishida T., Toda S., Nagata H. The preventive effect of human interferon-alpha preparation on upper respiratory disease. J Interferon Res. 1980 Fall;1(1):169–178. doi: 10.1089/jir.1980.1.169. [DOI] [PubMed] [Google Scholar]
  11. Isomura S., Ichikawa T., Miyazu M., Naruse H., Shibata M., Imanishi J., Matsuo A., Kishida T., Karaki T. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J. 1982 Sep;25(3):131–137. [PubMed] [Google Scholar]
  12. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  13. Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  14. Scott G. M., Phillpotts R. J., Wallace J., Secher D. S., Cantell K., Tyrrell D. A. Purified interferon as protection against rhinovirus infection. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1822–1825. doi: 10.1136/bmj.284.6332.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yeh T. J., McBride P. T., Overall J. C., Jr, Green J. A. Automated, quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol. 1982 Aug;16(2):413–415. doi: 10.1128/jcm.16.2.413-415.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES